With regard to hematological malignancies, parthanatos activation has been reported in 50% of AML patients undergoing AraC and anthracycline therapy, while resistant patients show low expression levels of PARP-1, classifying it as a potential biomarker of drug resistance [104]. Here, PARP1 is linked to hematologic disorder.